BioCentury
ARTICLE | Clinical News

Rucaparib regulatory update

November 19, 2012 8:00 AM UTC

The European Commission granted Orphan Drug designation for Clovis' rucaparib to treat ovarian cancer. The poly (ADP-ribose) polymerase-1 ( PARP-1) inhibitor is in Phase II testing to treat triple-neg...